Drug profile · INN
bretylium tosylate
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
bretylium tosylate (BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER) is a norepinephrine transporter substrate. Route of administration: injection. Current US regulatory status: approved.
Drug details — bretylium tosylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bretylium tosylate (BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER) is a norepinephrine transporter substrate. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Norepinephrine transporter substrate
Primary target: Sodium-dependent noradrenaline transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bretylium tosylate?
bretylium tosylate (BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER) is a norepinephrine transporter substrate. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for bretylium tosylate?
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER is a marketed brand name for bretylium tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bretylium tosylate?
bretylium tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.